Med Student Medical News about Satraplatin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Satraplatin: leading the new generation of oral platinum agents
Expert Opinion on Investigational Drugs, 11/06/09

Bhargava A et al. – Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA–approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate–resistant prostate cancer (CRPC), revealing an improvement in progression–free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel–refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.

<< Previous
Supraglottic swelling may not correlate with tongue swelling in...

Next >>
Development and validation of an Arabic version of the...

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The Sparc trial
Journal of Clinical Oncology, 10/08/09 Relevance Score: 94%